Literature DB >> 7740781

[Serodiagnosis and epidemiology of a California encephalitis group of infections in the Ryazan' region].

A M Butenko, V G Demikhov, M S Nedialkova, N A Lavrova.   

Abstract

Blood sera of 221 healthy residents of 4 districts of Ryazan region were tested in the neutralization test (NT) with Tahyna and Inkoo viruses. The sum of positive responses in the region was 40.7% on an average, this indicating numerous contacts of the local population with these agents. Blood sera of 520 patients with acute seasonal (May-September) fevers and neuroinfections were tested for antibodies to Tahyna and Inkoo viruses in serologic tests (NT and MAC-ELISA-IgM-antibody capture method). Etiologic relationship of the diseases with Tahyna and Inkoo viruses was detected in 51 (9.8%) cases. The patients developed two types of specific immune response, primary or secondary. The best diagnostic result was attained in testing paired sera of patients in NT and MAC-ELISA. MAC-ELISA helped etiologically diagnose the disease after a single testing of a blood serum collected in the acute period of the disease. Inkoo infection was more incident in subjects aged 21 to 40 in May and July-August. The majority of cases of Tahyna infection were diagnosed in subjects aged under 20 in June and July. The incubation period was from 3 to 7 days, the morbidity was sporadic.

Entities:  

Mesh:

Year:  1995        PMID: 7740781

Source DB:  PubMed          Journal:  Vopr Virusol        ISSN: 0507-4088


  2 in total

1.  Acute Human Inkoo and Chatanga Virus Infections, Finland.

Authors:  Niina Putkuri; Anu Kantele; Lev Levanov; Ilkka Kivistö; Markus Brummer-Korvenkontio; Antti Vaheri; Olli Vapalahti
Journal:  Emerg Infect Dis       Date:  2016-05       Impact factor: 6.883

2.  Seroprevalence and Risk Factors of Inkoo Virus in Northern Sweden.

Authors:  Magnus Evander; Niina Putkuri; Mats Eliasson; Olivia Wesula Lwande; Olli Vapalahti; Clas Ahlm
Journal:  Am J Trop Med Hyg       Date:  2016-02-29       Impact factor: 2.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.